Orforglipron, GLP-1 receptor agonist 1, LY3502970/oral GLP-1R agonist, appetite suppression, weight loss & glucos

Product Description
This product is Orforglipron (Chinese generic name: Aogelilong, former code name LY3502970 / OWL833), with CAS number 2212020-52-3. It is an oral non-peptide small-molecule compound developed by Eli Lilly and Company, belonging to GLP-1 receptor agonists. Unlike conventional similar peptide drugs that require parenteral administration, this product is chemically synthesized and can be formulated into oral tablets. Its molecular formula is C₄₈H₄₈F₂N₁₀O₅, with a molecular weight of approximately 882.96. It is normally a white to off-white powder, and its research-grade purity can reach over 98% (tested by HPLC). This product is an innovative drug active pharmaceutical ingredient and pharmaceutical intermediate, mainly supplied to research institutions, pharmaceutical enterprises for relevant research and development purposes.

Product Functions

Orforglipron targets the GLP-1 receptor — an important "switch" in the human body that regulates blood glucose and appetite. By activating this receptor, it can delay gastric emptying, boost satiety and suppress appetite, thereby helping lower blood glucose and reduce calorie intake. It is indicated for type 2 diabetes and weight management. Its most prominent feature is its form as an "oral small molecule": traditional drugs of the same class are mostly peptides that require parenteral administration, whereas this agent can be taken orally once daily for greater ease of use, making it one of the hot candidates in the field of innovative metabolic drugs.

Its specific functions can be summarized as follows:
Blood glucose regulation: It helps improve glycemic control by activating the GLP-1 receptor;
Appetite suppression and weight loss: It increases satiety and reduces food intake for weight management;
Convenient oral administration: Its small-molecule structure allows formulation into oral tablets for easy intake;
Once-daily dosing: It has a long duration of action with a low administration frequency;
Research tool for metabolic diseases: Applied in drug research and development for metabolic disorders such as diabetes and obesity.

Main Application Fields

This product is an innovative small-molecule drug substance and pharmaceutical intermediate. Its application is highly concentrated in the field of pharmaceutical research and development, and it is a popular candidate in the research and development of drugs for metabolic diseases.

Its main application areas can be summarized as follows:
New drug research and development for type 2 diabetes: Used in clinical and preclinical research of innovative oral hypoglycemic drugs;
Weight loss and weight management drugs: Used for the development of new drugs for chronic weight management;
Supply of pharmaceutical intermediates: Served as drug substances and key intermediates supplied to pharmaceutical enterprises and CDMOs;
Use as research reagents: Supplied to universities, research institutes and pharmaceutical laboratories as tool compounds for the study of GLP-1 receptor mechanisms;
Export trade and raw material supply: Provided as pharmaceutical raw materials to pharmaceutical companies, research institutions and traders, with specifications available upon customer request.